

Inhibitor-Decorated Polymer Conjugates Targeting Fibroblast Activation Protein

Petra Dvořáková,^{†,‡} Petr Bušek,[§] Tomáš Knedlík,^{†,||} Jiří Schimer,^{†,||} Tomáš Etrych,^{⊥,||} Libor Kostka,[⊥] Lucie Stollinová,[§] Šromová,[§] Vladimír Šubr,[⊥] Pavel Šácha,^{*,†,||} Aleksi Šedo,^{*,§} and Jan Konvalinka^{*,†,||}

[†]Institute of Organic Chemistry and Biochemistry of The Czech Academy of Sciences, Flemingovo nám 2, 16610 Prague 6, Czech Republic


[‡]Department of Cell Biology, Faculty of Science, Charles University, Viničná 7, 12843 Prague 2, Czech Republic

[§]Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, U Nemocnice 5, 12853 Prague 2, Czech Republic

^{||}Department of Biochemistry, Faculty of Science, Charles University, Hlavova 8, 12843 Prague 2, Czech Republic

[⊥]Institute of Macromolecular Chemistry, The Czech Academy of Sciences, Heyrovského nám 2, 16206 Prague 6, Czech Republic

Supporting Information



ABSTRACT: Proteases are directly involved in cancer pathogenesis. Expression of fibroblast activation protein (FAP) is upregulated in stromal fibroblasts in more than 90% of epithelial cancers and is associated with tumor progression. FAP expression is minimal or absent in most normal adult tissues, suggesting its promise as a target for the diagnosis or treatment of various cancers. Here, we report preparation of a polymer conjugate (an iBody) containing a FAP-specific inhibitor as the targeting ligand. The iBody inhibits both human and mouse FAP with low nanomolar inhibition constants but does not inhibit close FAP homologues dipeptidyl peptidase IV, dipeptidyl peptidase 9, and prolyl oligopeptidase. We demonstrate the applicability of this iBody for the isolation of FAP from cell lysates and blood serum as well as for its detection by ELISA, Western blot, flow cytometry, and confocal microscopy. Our results show the iBody is a useful tool for FAP targeting in vitro and potentially also for specific anticancer drug delivery.

INTRODUCTION

Proteases in tumor and stromal cells play an important role in cancer progression by promoting tumor cell invasion and metastasis as well as facilitating neovascularization.^{1–3} Because of their pathogenic role and differential expression in tumor tissue, some proteases, such as matrix metalloproteinases, hold promise as therapeutic and diagnostic targets. However, several large-scale clinical trials testing low-molecular-weight matrix metalloproteinase inhibitors failed to show improvement in clinical outcomes. This was most likely due to the imperfect specificity of the tested compounds, on-target side effects caused by interference with the physiological functions of the proteases, and the incompletely understood involvement of the targeted proteolytic enzymes as well as their substitutability by other proteases in disease progression.^{4,5}

Since its discovery in the late 1980s, fibroblast activation protein (FAP; seprase, surface expressed protease) has been

considered an interesting potential target for cancer therapeutics and diagnostics.⁶ FAP is expressed in stromal fibroblasts in more than 90% of epithelial cancers,⁶ and its expression is also increased in stromal cells in multiple myeloma⁷ and glioblastoma.⁸ In addition, FAP is expressed in malignant cells in glioblastoma⁸ and pancreatic,^{9,10} breast,¹¹ colorectal,¹² cervical,¹³ and oral squamous cell¹⁴ carcinomas. Although the effects of FAP are tumor specific and in certain cancers FAP may even act as a tumor suppressor,¹⁵ it has been established in several cases that high FAP expression contributes to the invasiveness and increased proliferation of the tumor cells.^{14,16,17} Moreover, FAP in the biotic material may be a prognostic marker of aggressive tumor progression, especially when expressed by cancer cells (recently reviewed in ref 18).

Received: May 30, 2017

Published: September 27, 2017

Recent studies also demonstrated that FAP expression is increased in various nonmalignant disease states accompanied by extracellular matrix remodeling such as in idiopathic pulmonary fibrosis,¹⁹ liver cirrhosis,²⁰ rheumatoid arthritis,²¹ myocardial infarction,²² and advanced atherosclerotic plaques.²³

With the exception of pancreatic alpha cells,²⁴ mesenchymal bone marrow cells,²⁵ and endometrial stroma during the proliferative phase,²⁶ FAP expression is minimal or absent in the majority of normal adult tissues.^{6,27,28} Its soluble form devoid of the cytoplasmic and transmembrane regions is physiologically present in blood plasma (known as antiplasmin-cleaving enzyme, APCE). The origin and function of blood plasma FAP are largely unknown.²⁹ Given the limited expression of FAP in human tissues under physiological conditions, FAP seems to be a promising molecule for targeting cancer stroma as well as some types of transformed cancer cells.

FAP is a type II transmembrane protein belonging to the S9B oligopeptidase subfamily of serine proteases. It consists of 760 amino acids: 6 form the N-terminal cytoplasmic tail, 20 the transmembrane part, and the remaining 734 amino acids are part of a large extracellular C-terminal domain.³⁰ FAP requires dimerization of two 97 kDa subunits for its catalytic activity³¹ and cleaves off dipeptides from the N-terminus of its substrates after a proline residue (N-Xxx-Pro-). In addition, FAP exhibits postproline endopeptidase activity,³² which is thought to contribute to the remodeling of the extracellular matrix.³³ Nevertheless, it is likely that at least some of the complex effects of FAP in cancer-associated fibroblasts and cancer cells are mediated by nonhydrolytic protein–protein interactions. For example, introduction of FAP endowed normal fibroblasts with an inflammatory phenotype, which was mediated by the activation of FAK–Src–JAK2 signaling pathway by the urokinase-type plasminogen activator receptor (uPAR), a known FAP-interacting membrane protein.³⁴ Similarly, the suppression of FAP in oral squamous cell carcinoma cells inactivated the PTEN/PI3K/AKT and Ras-ERK pathways and repressed the expression of genes regulating the epithelial–mesenchymal transition, thereby reducing the proliferation and invasiveness of these cells.¹⁴ Thus, the involvement of FAP in the pathogenesis of human malignancies is complex and seems to be cancer-type specific, which may have contributed to the failure of early clinical trials assessing FAP targeting with the rather nonspecific low-molecular-weight inhibitor talabostat³⁵ or the humanized antibody sibrotuzumab.³⁶

Recently, we have described novel biochemical tools called iBodies for the targeting of proteins with known ligands.³⁷ The iBodies are based on a water-soluble and biocompatible N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier decorated with low-molecular-weight compounds such as enzyme inhibitors used as targeting ligands. The use of iBodies offers several advantages over classical approaches with antibodies. The iBodies are highly modular and versatile; conjugates containing virtually any desired compound can be easily prepared. Synthetic HPMA conjugates are well-characterized compounds for biomedical applications and have long been used as carriers for drug delivery to solid tumors, often making use of the enhanced permeability and retention (EPR) effect.^{38–40} Importantly, the molecular weight of the HPMA backbone can be easily adjusted to specifically tailor the pharmacokinetic properties. To prepare a new platform that would allow FAP targeting in cancer, we set out to develop FAP-targeting iBodies.

Dipeptidyl peptidase IV (DPP-IV), the closest homologue of FAP, sharing 52% amino acid sequence identity, is a broadly expressed cell-surface serine protease involved in several physiological processes, including regulation of glucose metabolism⁴¹ and T-cell activation.⁴² Besides its physiological roles, DPP-IV was implicated in the pathogenesis of several cancers, acting as a tumor suppressor or promotor depending on the tumor type (recently reviewed in ref 43). The high selectivity of anti-FAP iBodies is critical to avoid interference with DPP-IV and to decrease the risk of undesired side effects. Jansen et al. recently developed low nanomolar FAP inhibitors based on a (4-quinolinoyl)glycyl-2-cyanopyrrolidine scaffold, which showed high selectivity against related proteases, including DPP-IV and prolyl-specific proteases prolyl oligopeptidase (PREP) and dipeptidyl peptidase 9 (DPP9).^{44–46}

In this work, we prepared anti-FAP iBody containing a highly specific FAP inhibitor as a targeting ligand and tested its utility using FAP-expressing malignant glioblastoma cells. We demonstrate that this iBody can be used for the specific detection of FAP in various biological matrices by a number of biochemical methods, and we show that it is suitable for the specific targeting and visualization of FAP as well as the inhibition of its enzymatic activity.

RESULTS

Expression of Recombinant Human and Mouse FAP and DPP-IV. To test the selectivity of the compounds described in this study, we prepared recombinant human and mouse FAP and DPP-IV bearing cleavable N-terminal purification tags (SF-tag or Avi-tag) (Figure 1a). All proteins were expressed in *Drosophila* S2 cells and purified via affinity chromatography according to previously published protocols (using Streptavidin Mutein matrix for Avi-tagged constructs⁴⁸ or Strep-Tactin resin for SF-tagged versions⁴⁹). Originally, all four proteins were prepared with an Avi-tag; however, the Avi-hFAP and Avi-mFAP expression yields were not sufficient for biochemical characterization and subsequent experiments. Therefore, we replaced the Avi-tag with the recently described SF-tag, which comprises two Strep-tags and a Flag-tag.⁴⁹ The resulting constructs, SF-hFAP and SF-mFAP, were expressed in larger quantities compared to their Avi-tagged counterparts and could be obtained in quantity and purity sufficient for their biochemical characterization, with overall yields of 0.7 and 0.2 mg, respectively (per 1 L of conditioned medium) (Figure 1b). Similarly, we obtained 0.1 and 0.2 mg of Avi-hDPP-IV and Avi-mDPP-IV, respectively. The kinetic properties of the SF-tagged and Avi-tagged proteins were virtually identical (data not shown).

Design, Synthesis, and Characterization of Anti-FAP iBody 1. To select the most suitable targeting ligand for FAP in terms of potency and selectivity, we prepared a small panel of FAP inhibitors (compounds 1–4; Scheme 1 and Figure 2a) and assessed their structure–activity relationships. Most importantly, we investigated the appropriate linkage of the targeting ligand to the polymer backbone. The compounds are based on the previously published structure of a FAP inhibitor with a (4-quinolinoyl)glycyl-2-cyanopyrrolidine scaffold^{44,45} and contain a PEG linker for attachment to the HPMA copolymer. We then determined IC₅₀ values of compounds 1–4 for SF-hFAP using a FAP activity inhibition assay. Compounds 1–3 exhibited comparable inhibition constants (0.23, 0.28, and 0.37 nM), whereas compound 4 was substantially less potent (4.8 nM) (Figure 2a). For further experiments, we chose compound 1 to




Figure 1. Design and purification of recombinant FAP and DPP-IV. (a) Schematic structures of the recombinant human and mouse FAP and DPP-IV proteins expressed in *Drosophila* S2 cells. The extracellular parts of human and mouse FAP containing Strep-tag II and Flag-tag were purified via Strep-Tactin affinity chromatography. The extracellular parts of human and mouse DPP-IV containing Avi-tag were purified via streptavidin murein affinity purification. (b) A silver-stained SDS-PAGE gel showing a typical two-round affinity purification of recombinant SF-hFAP protein expressed in *Drosophila* S2 cells. Load, concentrated medium; FT, flow-through; W1–W2, wash fractions; E1–E3, elution fractions. Ten microliters were loaded onto the gel, except for Load, FT-1, and FT-2 (0.5 μ L).

avoid steric problems after conjugation (long linker) and ensure the best inhibitory properties (difluoro substitution at C4 of the proline derivative).

Compound 1, together with an ATTO488 fluorophore and the affinity anchor biotin, were conjugated to the HPMA copolymer carrier, yielding an HPMA copolymer conjugate targeting FAP (iBody 1: $M_n = 110600$ g/mol, $M_w = 149900$ g/mol, $D = 1.36$; Figure 2b). As a negative control, a corresponding conjugate lacking the FAP inhibitor was prepared (iBody 2: $M_n = 80900$ g/mol, $M_w = 131000$ g/mol, $D = 1.62$). Attachment of compound 1 to the copolymer chain led to an increase in the IC_{50} value [IC_{50} (iBody 1) = 1.1 nM] (Figure 2c). Importantly, using a DPP-IV activity assay, we determined that iBody 1 is highly selective for FAP with IC_{50} for the FAP homologue DPP-IV more than 4 orders of magnitude higher ($IC_{50} > 10$ μ M) (Figure 2c). We also determined the IC_{50} values for iBody 1 toward mouse FAP and mouse DPP-IV and observed similar selectivity for FAP ($IC_{50} = 3.0$ nM and $IC_{50} > 10$ μ M, respectively). In addition, iBody 1 did not inhibit recombinant prolyl oligopeptidase (PREP) and dipeptidyl peptidase 9 (DPP9) (Figure 2c).

Use of Anti-FAP iBody 1 for Detection and Visualization of FAP. We used surface plasmon resonance (SPR) to evaluate the interaction between iBody 1 and FAP (Figure 3a). iBody 1 was immobilized to a neutravidin layer via biotin, and four concentrations of recombinant SF-hFAP were loaded. The SPR analysis indicated a relatively high association rate ($k_{on} = 3860$ $M^{-1} s^{-1}$) and remarkably low dissociation rate ($k_{off} < 2 \times 10^{-5}$ s^{-1}), which was under the detection limit of our SPR instrument. The resulting dissociation constant ($K_D < 6$ nM) is

comparable with the IC_{50} value obtained from the FAP activity assay. Concordantly, we confirmed that inhibition of FAP enzymatic activity persists even when FAP-containing cell lysates preincubated with effective concentrations of anti-FAP iBody were diluted to decrease the iBody concentration prior to the enzymatic assay. In contrast, the inhibition by the low-molecular-weight (4-quinolinoyl)glycyl-2-cyanopyrrolidine-based FAP inhibitors was reversible in the same experimental setup (data not shown).


We tested the anti-FAP conjugate in several biochemical applications. Using iBody 1 immobilized to streptavidin agarose via biotin, we pulled down FAP from a cell lysate of U251 cells stably transfected with human FAP (U251_FAP+; see the “Biochemical Methods” section in the Supporting Information for the discussion of the cell line denomination) (Figure 3b). As negative controls, we used iBody 2, which lacks the FAP inhibitor, and blank streptavidin agarose (NC-SA) to show potential nonspecific binding to HPMA copolymer backbone and/or the streptavidin agarose resin (Figure 3b). The presence of isolated FAP was verified by LC-MS/MS, which detected FAP protein in the iBody 1 elution sample. Using the same setup, we also successfully isolated FAP protein from human blood plasma (verified by LC-MS/MS; data not shown), further confirming the functionality of anti-FAP conjugates in complex biological samples.

Additionally, we developed sandwich ELISA for FAP quantification employing iBody 1 as a substitute for the detection antibody (Figure 3c). Recombinant SF-hFAP was first captured by the FAP-specific monoclonal antibody F-19 and then detected with iBody 1, followed by incubation with neutravidin–HRP conjugate. The detection limit of this newly developed ELISA was as low as 0.4 ng/mL of FAP.

iBody 1 (followed by IRDye 800CW streptavidin conjugate) could also be used to visualize FAP on a “semi-native” Western blot (Figure 3d). Both recombinant SF-tagged FAP (SF-hFAP) and endogenous full-length FAP migrated at around 130 kDa, corresponding to FAP dimers; the detection limit was about 50 ng of FAP (Figure 3d).

Application of Anti-FAP iBody 1 for Imaging of FAP-Expressing Cells. We tested the suitability of iBody 1 as a tool for the specific imaging of FAP-positive cells using confocal microscopy (Figure 4a,d) and flow cytometry (Figure 4b,c). Live cells expressing (U251_FAP+) or not expressing (U251_FAP–) FAP were incubated with anti-FAP iBody 1; iBody 2, which lacks the FAP inhibitor, was used as a negative control. Confocal microscopy imaging showed that iBody 1 binds only to FAP-expressing cells and not to cells lacking FAP, whereas control iBody 2 did not bind to any of the cells analyzed (Figure 4a). Upon binding to FAP on the cell surface, iBody 1 underwent slow internalization, as evidenced by the accumulation of the signal inside cells after prolonged incubation. Similar results were obtained with cells transfected with mouse FAP (data not shown).

The binding of anti-FAP iBody 1 to mouse FAP was also confirmed by flow cytometry. Anti-FAP iBody 1 strongly stained mouse GL261 glioma cells transfected with mouse FAP, whereas neither the FAP-negative parental cell line GL261 nor GL261 cells transfected with mouse DPP-IV were stained by the conjugate (Figure 4b). We further analyzed the utility of the compounds in detecting endogenous levels of FAP expression. Using flow cytometry, FAP expression was visualized in cultured human fibroblasts and human glioblastoma U87 cells, which are known to express the protein,⁵⁰ by anti-FAP

Scheme 1. Synthesis of Compounds 1–4, Specific Inhibitors of FAP Modified with PEG Linkers^a

^aReagents and conditions: (a*) described in ref 47; (a) SOCl_2 , MeOH, reflux; (b) NaH, *t*-butyl 2-bromoacetate, DMF, $-80\text{ }^\circ\text{C}$ to RT; (c) TFA; (d) TBTU, DIEA, $\text{NH}_2\text{-PEG}_n\text{-NH-BOC}$ ($n = 5$, or $n = 15$), DMF; (e) 5 M NaOH/ H_2O , THF/MeOH; (f) (1) TSTU, DIEA, DMF, (2) (*S*)-2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethanaminium chloride or (*S*)-2-(2-cyanopyrrolidin-1-yl)-2-oxoethanaminium chloride; (g) Ts-OH, ACN.

iBody 1 followed by an amplification step with a streptavidin–phycoerythrin conjugate (Figure 4c). Finally, anti-FAP iBody 1 was used to visualize FAP-transfected tumor cells in frozen tissue sections of glioma tumor xenografts (Figure 4d).

Collectively, these data suggest the applicability of anti-FAP iBodies in a broad spectrum of methodologies traditionally utilizing antibodies.

DISCUSSION

Multiple proteases are involved in oncogenesis. FAP, along with other proteases, is proposed to participate in the processes of cell adhesion, invasion, migration, and tumor neovascularization.⁵¹ However, in contrast to most other cancer-associated proteases, FAP is expressed very sparsely in healthy adult tissues. In cancerous tissues, FAP is characteristically present in stromal cells as well as in the transformed elements of several malignancies.⁵¹ This makes FAP a promising potential target to exploit for cancer therapeutics and/or diagnostics. Recently, we described the iBody concept for specific targeting of enzymes.³⁷ In this work, we aimed to prepare anti-FAP iBodies and demonstrate their potential to specifically bind FAP and FAP-expressing cells.

To identify the most potent and specific FAP-targeting ligand, we synthesized and characterized four FAP inhibitors based on the (4-quinolinyl)glycyl-2-cyanopyrrolidine scaffold, which has high potency and selectivity for FAP.⁴⁴ The

inhibitors were synthesized with PEG linkers of two different lengths, as we had previously observed that short linkers impaired binding of the protein target to the inhibitor molecule “immobilized” on the polymer backbone. We prepared inhibitors with or without a 4,4-difluoro substitution of the 2-cyanopyrrolidine moiety, as Jansen et al. showed that this substitution leads to more potent FAP binding and improved selectivity with respect to the close FAP homologue prolyl oligopeptidase.⁴⁵ Conjugation of compound 1 to the HPMA copolymer resulted in a 5-fold increase in the IC_{50} value. This was somewhat surprising, as we observed a significant drop in IC_{50} value for the iBody targeting GCPH.³⁷ Nevertheless, anti-FAP iBody 1 is a low nanomolar binder of FAP, which is still more than sufficient for effective *in vitro* and *in vivo* targeting. Highly specific discrimination between FAP and its close homologue DPP-IV, an almost ubiquitously expressed multifunctional protease,⁵² is essential to prevent off-target effects of anti-FAP iBodies *in vivo*. We showed that iBody 1 is highly selective for FAP, exhibiting a more than four-order-of-magnitude lower IC_{50} for FAP than for DPP-IV. Therefore, even hundred nanomolar concentrations should lead to specific FAP targeting. We also verified that IC_{50} values of iBody 1 toward other FAP homologues, prolyl oligopeptidase (PREP) and dipeptidyl peptidase 9 (DPP9), are more than three-orders-of-magnitude higher than for FAP itself, meaning that iBody 1




Figure 2. Structures of FAP inhibitors and anti-FAP polymer conjugate iBody 1 and their kinetic characterization. (a) The effect of prolyl moiety modification of the (4-quinolinoyl)glycyl-2-cyanopyrrolidine scaffold and PEG linker length on the kinetic properties of the tested inhibitors. The IC_{50} values for modified inhibitors with or without fluorine substitution and PEG linkers of various lengths are presented as mean $\pm$ standard deviation. Measurements were performed in duplicate. (b) Schematic structure of anti-FAP polymer conjugate (iBody 1) containing an ATTO488 fluorophore, an affinity anchor (biotin), and compound 1, the FAP-specific inhibitor. (c) Comparison of IC_{50} values of the FAP inhibitor and the anti-FAP iBody toward recombinant FAP, DPP-IV, DPP9, and PREP (IC_{50} values are presented as mean $\pm$ standard deviation).




Figure 3. Application of anti-FAP iBody 1 in biochemical methods. (a) SPR analysis of SF-hFAP binding to immobilized iBody 1 ($K_D < 6$ nM). (b) Affinity isolation of FAP from FAP-transfected U251 (U251_FAP+) cell lysate using iBody 1. iBody 2 (lacking FAP inhibitor) and blank streptavidin agarose (NC-SA) were used as negative controls. Load = U251_FAP+ cell lysate. (c) Sandwich ELISA for quantification of FAP using iBody 1 and anti-FAP F-19 antibody as a detection "agent" and a capture antibody, respectively. Each sample was measured in triplicate; values are presented as the mean $\pm$ standard deviation. (d) Western blot visualization of FAP using iBody 1 followed by an IRDye 800CW streptavidin conjugate. Purified recombinant human FAP (SF-hFAP) and a lysate of U251_FAP+ cells were used. The right section refers to the membrane probed with IRDye 800CW streptavidin conjugate only.

keeps the selectivity for FAP over these predominantly intracellularly localized homologues as well.

In contrast to antibodies, which target surface epitopes, the binding of iBodies relies on a specific interaction between the

inhibitor molecule and the active site of the enzyme, which is usually the most conserved part of a protein molecule. Therefore, we expected anti-FAP iBody to bind FAP orthologues with similar affinity. Indeed, we found that iBody




Figure 4. Detection and visualization of FAP on cells using anti-FAP iBody 1. (a) Confocal microscopy analysis of cells expressing and not expressing FAP. Cells with inducible FAP expression were incubated with 200 nM iBody 1 (at 37 °C for 1 h), which was then visualized by confocal microscopy; the cell nuclei were stained with Hoechst H34580 dye. (b) Flow cytometry detection of FAP expression in GL261 cells transfected with mouse FAP but not in cells transfected with the closely related mouse DPP-IV. Nontransfected GL261 cells stained with iBody 1 and streptavidin–PE conjugate, and FAP–GL261 transfectants stained with streptavidin–PE conjugate only were used as negative controls. (c) Flow cytometry detection of endogenous FAP expression in human fibroblasts and U87 glioma cells using anti-FAP iBody 1. GL261 cells incubated with iBody 1 and streptavidin–PE conjugate and human fibroblasts incubated with streptavidin–PE conjugate only were used as negative controls. (d) Immunohistochemistry on frozen sections of a tumor (delineated by a dashed line) generated by xenotransplantation of FAP-transfected glioma cells into mouse brain.

1 interacts with mouse FAP with an inhibition constant comparable to that of human FAP. This extends the applicability of anti-FAP iBodies, suggesting that they can be used as a versatile instrument for animal model experiments in preclinical translational studies.

We used various biochemical methods to assess the potential of iBody 1 for FAP targeting in vitro. Using SPR, we characterized iBody 1 binding to FAP and determined its K_D . Importantly, these results suggested the formation of a stable complex between FAP and its targeting iBody despite the fact that inhibition by the low-molecular-weight (4-quinolinoyl)-glycyl-2-cyanopyrrolidine-based FAP inhibitors is reversible.⁴⁵ When bound to streptavidin agarose resin, iBody 1 specifically pulled down FAP from complex protein matrices, including cell lysate and human blood plasma. As seen in Figure 3b, the negative control experiment with blank streptavidin agarose showed that the nonspecifically isolated proteins are adsorbed to the agarose resin and not to the HPMA conjugate backbone.

For quantitative assays of FAP, we developed a sandwich ELISA using iBody 1 in place of the detection antibody (Figure 3c). Even without optimizing the assay, the limit of detection of the antibody–iBody sandwich ELISA was comparable to that of the commercially available ELISA (Human FAP DuoSet ELISA, no. DY3715; R&D Systems, Inc.). FAP could also be detected on Western blot, which is somewhat surprising as iBody binding requires an intact active site, while SDS-PAGE and blotting generally lead to protein structure destabilization. However, FAP apparently preserved its native structure during these processes and was recognized by iBody 1. The observed FAP band migrating at about 130 kDa corresponds to the dimeric form of FAP, suggesting that the FAP dimer was not dissociated in the used experimental setup.

Next, we tested iBody 1 in cell culture experiments. Live cell imaging using confocal microscopy confirmed the high selectivity of anti-FAP iBody for FAP and revealed negligible nonspecific binding to cells. Up to micromolar concentrations

of the anti-FAP polymer conjugate did not stain cells not expressing FAP. Our data showed that the FAP-iBody complex is internalized, which is beneficial for future drug delivery concepts exploiting FAP iBodies in cancer therapy. In addition to cell culture experiments with human FAP, we also showed that iBody 1 specifically stained GL261 cells transfected with mouse FAP, confirming its possible use in mouse models. Finally, we used iBody 1 to detect and visualize FAP on cells within complex tissue by performing immunohistochemistry experiments with frozen tissue sections.

CONCLUSION

We designed, synthesized, and characterized a novel type of a highly selective FAP targeting agent, an iBody based on an HPMA copolymer decorated with a FAP inhibitor. The specificity, modularity, and versatility of the anti-FAP iBody make it suitable for a broad spectrum of biochemical and biomedical applications. Thus, anti-FAP iBodies may represent an attractive theranostic tool for future in vivo imaging and selective drug delivery into the tumor microenvironment.

EXPERIMENTAL SECTION

Chemistry. All chemicals were purchased from Sigma-Aldrich, unless stated otherwise. All inhibitors tested in the biological assays were purified using preparative scale HPLC Jasco PU-975 (flow rate 10 mL/min, water phase containing 0.1% of TFA; gradient shown for each compound, including R_t) equipped with UV detector UV-975 and with column Waters YMC-PACK ODS-AM C18 prep column, 5 μ m, 20 mm $\times$ 250 mm. The purity of compounds was tested on analytical Jasco PU-1580 HPLC (flow rate 1 mL/min, invariable gradient 2–100% ACN in 30 min, R_t shown for each compound, water phase contained 0.1% of TFA) with column Watrex C18 analytical column, 5 μ m, 250 mm $\times$ 5 mm. The final inhibitors were all at least of 99% purity. Structure was further confirmed by HRMS at LTQ Orbitrap XL (Thermo Fisher Scientific) and by NMR (Bruker Avance I 400 MHz).

(S)-1-((4-((2-(2-Cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-carbamoyl)quinolin-7-yl)oxy)-2-oxo-6,9,12,15,18-pentaoxa-3-azapentacontan-50-aminium 2,2,2-Trifluoroacetate (1). The crude evaporated reaction mixture of compound 10a was dissolved in 1.5 mL of ACN and 400 mg of *p*-toluenesulfonic acid were added in one portion. The reaction was left stirring overnight, after which it was evaporated and the product was isolated using preparative scale HPLC (grad, 10–40% ACN in 50 min; R_t = 36 min) 133 mg isolated upon dry freezing (isolated yield over two steps = 57%). Analytical HPLC: R_t = 16.5 min. HRMS: (ESI+) m/z for $C_{51}H_{83}O_{19}N_6F_2$ [$M + H$]⁺ calcd 1121.56756, found 1121.56767.

(S)-1-((4-((2-(2-Cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-carbamoyl)quinolin-7-yl)oxy)-2-oxo-6,9,12,15,18-pentaoxa-3-azapentacontan-50-aminium 2,2,2-Trifluoroacetate (2). The crude evaporated intermediate from previous reaction (compound 10b) was dissolved in 1 mL of ACN and 100 mg of *p*-toluenesulfonic acid was added in one portion. The reaction mixture was left stirring overnight, after which it was evaporated and the product purified (gradient, 10–40 ACN in 50 min; R_t = 29 min) 6 mg of oily yellowish substance obtained upon dry freezing (isolated yield = 30%). Analytical HPLC: R_t = 14.0 min. HRMS: (ESI+) m/z for $C_{51}H_{83}O_{19}N_6F_2$ [$M + H$]⁺ calcd 681.30449, found 681.30541.

(S)-1-((4-((2-(2-Cyanopyrrolidin-1-yl)-2-oxoethyl)carbamoyl)quinolin-7-yl)oxy)-2-oxo-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48-pentadeca-3-azapentacontan-50-aminium 2,2,2-trifluoroacetate (3). Crude evaporated reaction mixture from the previous reaction (compound 10c; product theoretically 79 μ mol, 1.0 equiv) was dissolved in 2 mL of ACN and 150 mg of Tos-OH-H₂O (790 μ mol, 10.0 equiv) were added in one portion and the deprotection was left to proceed overnight. The reaction mixture was then evaporated, and the crude product was purified on a

preparative scale HPLC (grad, 10–40% ACN in 50 min; R_t = 36 min). (Note: deprotection with TFA leads to a major side reaction where isobutylene is added on the nitrile group.) Analytical HPLC: R_t = 16.1 min. HRMS: (ESI+) m/z for $C_{51}H_{83}O_{19}N_6$ [$M + H$]⁺ calcd 1085.58640, found 1085.58646.

(S)-1-((4-((2-(2-Cyanopyrrolidin-1-yl)-2-oxoethyl)carbamoyl)quinolin-7-yl)oxy)-2-oxo-6,9,12,15,18-pentaoxa-3-azacosan-20-aminium 2,2,2-trifluoroacetate (4). First, 30 mg of compound 10d (40 μ mol, 1.0 equiv) were dissolved in 750 μ L of ACN and 23 mg of Tos-OH-H₂O were added in one portion. The reaction mixture was monitored by analytical HPLC. After 16 h, the reaction mixture was evaporated and the product was purified using preparative scale HPLC (gradient, 20–60% ACN in 50 min; R_t = 30 min) 17 mg of oily yellowish substance obtained upon dry freezing (isolated yield = 56%). Note: the reaction does undergo the deprotection using TFA as well, however, it is much less clean, probably due to addition of *t*-butyl cation on nitrile group. Analytical HPLC: R_t = 14.2 min. HRMS: (ESI+) m/z for $C_{31}H_{45}O_9N_6$ [$M + H$]⁺ calcd 645.32425, found 645.32420.

iBody 1. Copolymer precursor poly(HPMA-co-Ma- β -Ala-TT) (15 mg; M_n = 61700 g/mol, M_w = 66600 g/mol, $\bar{D}$ = 1.08; 11.7 mol % TT; the preparation is described in the Supporting Information), compound 1 (3.78 mg dissolved in 36 μ L of DMSO), ATTO488-NH₂ (0.75 mg), and *N*-(2-aminoethyl)biotinamid hydrobromide (biotin-NH₂) (2 mg) were dissolved in 0.1 mL of *N,N*-dimethylacetamide (DMA). Then 4.9 μ L of *N,N*-diisopropylethylamine (DIPEA) was added. Reaction was carried out for 4 h at room temperature, and then 2 μ L of 1-aminopropan-2-ol was added and the reaction was stirred for 10 min. Copolymer conjugate poly(HPMA-co-Ma- β -Ala-compound1-co-Ma- β -Ala-ATTO488-co-Ma- β -Ala-NH-biotin) (iBody 1) was isolated by precipitation into a mixture of acetone:diethyl ether (3:1), filtered off, washed with acetone and diethyl ether, and dried in vacuum. Polymer conjugate was purified on chromatography column Sephadex LH-20 in methanol, precipitated into diethyl ether, filtered off, and dried in vacuum. Yield of the iBody 1 (M_n = 110600 g/mol, M_w = 149900 g/mol, $\bar{D}$ = 1.36) was 17 mg, and the content of compound 1 was 13.6 wt %, the content of biotin was 4.8 wt %, and the content of ATTO488 was 2.3 wt %.

iBody 2. Polymer precursor (50 mg; M_n = 59600 g/mol, M_w = 72700 g/mol, $\bar{D}$ = 1.22; 11.7 mol % TT; the preparation described in the Supporting Information), ATTO488 (2.5 mg), and biotin-NH₂ (6 mg) were dissolved in 0.5 mL of DMSO and then 6.8 μ L of *N,N*-diisopropylethylamine (DIPEA) was added. Reaction was carried out for 4 h at room temperature, and then 2 μ L of 1-aminopropan-2-ol was added and the reaction was stirred for 10 min. Copolymer conjugate poly(HPMA-co-Ma- β -Ala-ATTO488-co-Ma- β -Ala-NH-biotin) (iBody 2) was isolated by precipitation into a mixture of acetone:diethyl ether (3:1), filtered off, washed with acetone and diethyl ether, and dried in vacuum. Polymer conjugate was purified on chromatography column Sephadex LH-20 in methanol, precipitated into diethyl ether, filtered off, and dried in vacuum. Yield of the iBody 2 (M_n = 80900 g/mol, M_w = 131000 g/mol, $\bar{D}$ = 1.62) was 40 mg, the content of ATTO488 was 4.1 wt %, and the content of biotin was 5.4 wt %.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmedchem.7b00767.

Synthesis of intermediate compounds, polymers, and polymer conjugates; biochemical methods (PDF)
Molecular formula strings (CSV)

AUTHOR INFORMATION

Corresponding Authors

*For J.K.: phone, 00420 220 183 218; fax, 00420 220 183 578; E-mail, jan.konvalinka@uochb.cas.cz.

*For A.S.: phone, 00420 224 965 826; E-mail, aleksi@cesnet.cz.

*For P.Š.: phone, 00420 220 183 452; fax, 00420 220 183 578; E-mail, pavelsacha@gmail.com.

ORCID

Tomáš Etrych: 0000-0001-5908-5182

Jan Konvalinka: 0000-0003-0695-9266

Author Contributions

P.D., P.B., and T.K. contributed equally. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare the following competing financial interest(s): A patent application (PCT/CZ2016/05003) has been filed related to this work.

ACKNOWLEDGMENTS

We thank Jana Starková, Karolína Šrámková, Květoslava Vlašicová, and Karin Roubíčková for their excellent technical support, Stanislava Matějková and Štefan Štanga for elemental analyses, Martin Hubálek for protein mass spectrometry, and Hillary Hoffman for language editing. This work was supported by IOCB and Gilead Research Center Prague, grant no. 15-31379A from the Ministry of Health of the Czech Republic, UNCE 204013, and Progres Q28 projects from the Charles University, grant no. LM2015064 of the EATRIS-CZ and InterBioMed project LO 1302 from the Ministry of Education of the Czech Republic.

ABBREVIATIONS USED

FAP, fibroblast activation protein; DPP-IV, dipeptidyl peptidase-IV; SF-hFAP, extracellular portion of human FAP (aa 26–760) with N-terminal SF-tag; SF-mFAP, extracellular portion of mouse FAP (aa 26–761) with N-terminal SF-tag; Avi-hDPP-IV, extracellular portion of human DPP-IV (aa 29–766) with N-terminal Avi-tag; Avi-mDPP-IV, extracellular portion of mouse DPP-IV (aa 29–760) with N-terminal Avi-tag; DPP9, dipeptidyl peptidase 9; PREP, prolyl oligopeptidase; HPMA, N-(2-hydroxypropyl)methacrylamide

REFERENCES

- (1) Sevenich, L.; Joyce, J. A. Pericellular proteolysis in cancer. *Genes Dev.* **2014**, *28*, 2331–2347.
- (2) Bonnans, C.; Chou, J.; Werb, Z. Remodelling the extracellular matrix in development and disease. *Nat. Rev. Mol. Cell Biol.* **2014**, *15*, 786–801.
- (3) Basset, P.; Bellocq, J. P.; Wolf, C.; Stoll, I.; Hutin, P.; Limacher, J. M.; Podhajcer, O. L.; Chenard, M. P.; Rio, M. C.; Chambon, P. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. *Nature* **1990**, *348*, 699–704.
- (4) Cathcart, J.; Pulkoski-Gross, A.; Cao, J. Targeting matrix metalloproteinases in cancer: bringing new life to old ideas. *Genes Dis.* **2015**, *2*, 26–34.
- (5) Zucker, S.; Cao, J.; Chen, W. T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. *Oncogene* **2000**, *19*, 6642–6650.
- (6) Garin-Chesa, P.; Old, L. J.; Rettig, W. J. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. *Proc. Natl. Acad. Sci. U. S. A.* **1990**, *87*, 7235–7239.
- (7) Ge, Y.; Zhan, F. G.; Barlogie, B.; Epstein, J.; Shaughnessy, J.; Yaccoby, S. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. *Br. J. Haematol.* **2006**, *133*, 83–92.
- (8) Busek, P.; Balaziová, E.; Matrasova, I.; Hilser, M.; Tomas, R.; Syrucek, M.; Zemanova, Z.; Krepela, E.; Belacek, J.; Sedo, A. Fibroblast activation protein alpha is expressed by transformed and stromal cells

and is associated with mesenchymal features in glioblastoma. *Tumor Biol.* **2016**, *37*, 13961–13971.

- (9) Shi, M.; Yu, D. H.; Chen, Y.; Zhao, C. Y.; Zhang, J.; Liu, Q. H.; Ni, C. R.; Zhu, M. H. Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. *World J. Gastroenterol.* **2012**, *18*, 840–846.

- (10) Busek, P.; Vanickova, Z.; Hrabal, P.; Brabec, M.; Fric, P.; Zavoral, M.; Skrha, J.; Kmochova, K.; Laclav, M.; Bunganic, B.; Augustyns, K.; Van der Veken, P.; Sedo, A. Increased tissue and circulating levels of dipeptidyl peptidase-IV enzymatic activity in patients with pancreatic ductal adenocarcinoma. *Pancreatol.* **2016**, *16*, 829–838.

- (11) Kelly, T.; Kechelava, S.; Rozypal, T. L.; West, K. W.; Korourian, S. Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancers. *Mod. Pathol.* **1998**, *11*, 855–863.

- (12) Iwasa, S.; Jin, X.; Okada, K.; Mitsumata, M.; Ooi, A. Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer. *Cancer Lett.* **2003**, *199*, 91–98.

- (13) Jin, X.; Iwasa, S.; Okada, K.; Mitsumata, M.; Ooi, A. Expression patterns of seprase, a membrane serine protease, in cervical carcinoma and cervical intraepithelial neoplasm. *Anticancer Res.* **2003**, *23*, 3195–3198.

- (14) Wang, H.; Wu, Q.; Liu, Z.; Luo, X.; Fan, Y.; Liu, Y.; Zhang, Y.; Hua, S.; Fu, Q.; Zhao, M.; Chen, Y.; Fang, W.; Lv, X. Downregulation of FAP suppresses cell proliferation and metastasis through PTEN/PI3K/AKT and Ras-ERK signaling in oral squamous cell carcinoma. *Cell Death Dis.* **2014**, *5*, e1155.

- (15) Ramirez-Montagut, T.; Blachere, N. E.; Sviderskaya, E. V.; Bennett, D. C.; Rettig, W. J.; Garin-Chesa, P.; Houghton, A. N. FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor. *Oncogene* **2004**, *23*, 5435–5446.

- (16) Gong, Q.; Shi, W.; Li, L.; Wu, X.; Ma, H. Ultrasensitive fluorescent probes reveal an adverse action of dipeptide peptidase IV and fibroblast activation protein during proliferation of cancer cells. *Anal. Chem.* **2016**, *88*, 8309–8314.

- (17) Tulley, S.; Chen, W. T. Transcriptional regulation of seprase in invasive melanoma cells by transforming growth factor-beta signaling. *J. Biol. Chem.* **2014**, *289*, 15280–15296.

- (18) Liu, F.; Qi, L.; Liu, B.; Liu, J.; Zhang, H.; Che, D.; Cao, J.; Shen, J.; Geng, J.; Bi, Y.; Ye, L.; Pan, B.; Yu, Y. Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis. *PLoS One* **2015**, *10*, e0116683.

- (19) Acharya, P. S.; Zukas, A.; Chandan, V.; Katzenstein, A. L.; Pure, E. Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. *Hum. Pathol.* **2006**, *37*, 352–360.

- (20) Levy, M. T.; McCaughan, G. W.; Abbott, C. A.; Park, J. E.; Cunningham, A. M.; Muller, E.; Rettig, W. J.; Gorrell, M. D. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodeling interface in human cirrhosis. *Hepatology* **1999**, *29*, 1768–1778.

- (21) Bauer, S.; Jendro, M. C.; Wadle, A.; Kleber, S.; Stenner, F.; Dinser, R.; Reich, A.; Faccin, E.; Godde, S.; Dinges, H.; Muller-Ladner, U.; Renner, C. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. *Arthritis Res. Ther.* **2006**, *8*, R171.

- (22) Tillmanns, J.; Hoffmann, D.; Habbaba, Y.; Schmitto, J. D.; Sedding, D.; Fraccarollo, D.; Galuppo, P.; Bauersachs, J. Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction. *J. Mol. Cell. Cardiol.* **2015**, *87*, 194–203.

- (23) Brokopp, C. E.; Schoenauer, R.; Richards, P.; Bauer, S.; Lohmann, C.; Emmert, M. Y.; Weber, B.; Winnik, S.; Aikawa, E.; Graves, K.; Genoni, M.; Vogt, P.; Luscher, T. F.; Renner, C.; Hoerstrup, S. P.; Matter, C. M. Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata. *Eur. Heart J.* **2011**, *32*, 2713–2722.

- (24) Busek, P.; Hrabal, P.; Fric, P.; Sedo, A. Co-expression of the homologous proteases fibroblast activation protein and dipeptidyl peptidase-IV in the adult human Langerhans islets. *Histochem. Cell Biol.* **2015**, *143*, 497–504.
- (25) Bae, S.; Park, C. W.; Son, H. K.; Ju, H. K.; Paik, D.; Jeon, C. J.; Koh, G. Y.; Kim, J.; Kim, H. Fibroblast activation protein alpha identifies mesenchymal stromal cells from human bone marrow. *Br. J. Haematol.* **2008**, *142*, 827–830.
- (26) Dolznig, H.; Schweifer, N.; Puri, C.; Kraut, N.; Rettig, W. J.; Kerjaschki, D.; Garin-Chesa, P. Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. *Cancer Immun.* **2005**, *5*, 10.
- (27) Monsky, W. L.; Lin, C. Y.; Aoyama, A.; Kelly, T.; Akiyama, S. K.; Mueller, S. C.; Chen, W. T. A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. *Cancer Res.* **1994**, *54*, 5702–5710.
- (28) Rettig, W. J.; Garin-Chesa, P.; Beresford, H. R.; Oettgen, H. F.; Melamed, M. R.; Old, L. J. Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. *Proc. Natl. Acad. Sci. U. S. A.* **1988**, *85*, 3110–3114.
- (29) Lee, K. N.; Jackson, K. W.; Christiansen, V. J.; Lee, C. S.; Chun, J. G.; McKee, P. A. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. *Blood* **2006**, *107*, 1397–1404.
- (30) Goldstein, L. A.; Ghersi, G.; Pineiro-Sanchez, M. L.; Salamone, M.; Yeh, Y. Y.; Flessate, D.; Chen, W. T. Molecular cloning of seprase: a serine integral membrane protease from human melanoma. *Biochim. Biophys. Acta, Mol. Basis Dis.* **1997**, *1361*, 11–19.
- (31) Pineiro-Sanchez, M. L.; Goldstein, L. A.; Dodt, J.; Howard, L.; Yeh, Y.; Chen, W. T. Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. *J. Biol. Chem.* **1997**, *272*, 7595–7601.
- (32) Edosada, C. Y.; Quan, C.; Wiesmann, C.; Tran, T.; Sutherlin, D.; Reynolds, M.; Elliott, J. M.; Raab, H.; Fairbrother, W.; Wolf, B. B. Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity. *J. Biol. Chem.* **2006**, *281*, 7437–7444.
- (33) Lee, H. O.; Mullins, S. R.; Franco-Barraza, J.; Valianou, M.; Cukierman, E.; Cheng, J. D. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. *BMC Cancer* **2011**, *11*, 245.
- (34) Yang, X. G.; Lin, Y. L.; Shi, Y. H.; Li, B. J.; Liu, W. R.; Yin, W.; Dang, Y. J.; Chu, Y. W.; Fan, J.; He, R. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. *Cancer Res.* **2016**, *76*, 4124–4135.
- (35) Narra, K.; Mullins, S. R.; Lee, H. O.; Strzemkowski-Brun, B.; Magalong, K.; Christiansen, V. J.; McKee, P. A.; Egleston, B.; Cohen, S. J.; Weiner, L. M.; Meropol, N. J.; Cheng, J. D. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer. *Cancer Biol. Ther.* **2007**, *6*, 1691–1699.
- (36) Hofheinz, R. D.; al-Batran, S. E.; Hartmann, F.; Hartung, G.; Jager, D.; Renner, C.; Tanswell, P.; Kunz, U.; Amelsberg, A.; Kuthan, H.; Stehle, G. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibtrozumab in patients with metastatic colorectal cancer. *Oncol. Res. Treat.* **2003**, *26*, 44–48.
- (37) Sacha, P.; Knedlik, T.; Schimer, J.; Tykvar, J.; Parolek, J.; Navratil, V.; Dvorakova, P.; Sedlak, F.; Ulbrich, K.; Strohalm, J.; Majer, P.; Subr, V.; Konvalinka, J. iBodies: modular synthetic antibody mimetics based on hydrophilic polymers decorated with functional moieties. *Angew. Chem., Int. Ed.* **2016**, *55*, 2356–2360.
- (38) Ulbrich, K.; Hola, K.; Subr, V.; Bakandritsos, A.; Tucek, J.; Zboril, R. Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies. *Chem. Rev.* **2016**, *116*, 5338–5431.
- (39) Dozono, H.; Yanazume, S.; Nakamura, H.; Etrych, T.; Chytil, P.; Ulbrich, K.; Fang, J.; Arimura, T.; Douchi, T.; Kobayashi, H.; Ikoma, M.; Maeda, H. HPMA copolymer-conjugated pirarubicin in multimodal treatment of a patient with stage IV prostate cancer and extensive lung and bone metastases. *Targeted Oncol.* **2016**, *11*, 101–106.
- (40) Nakamura, H.; Koziolova, E.; Chytil, P.; Tsukigawa, K.; Fang, J.; Haratake, M.; Ulbrich, K.; Etrych, T.; Maeda, H. Pronounced cellular uptake of pirarubicin versus that of other anthracyclines: comparison of HPMA copolymer conjugates of pirarubicin and doxorubicin. *Mol. Pharmaceutics* **2016**, *13*, 4106–4115.
- (41) Marguet, D.; Baggio, L.; Kobayashi, T.; Bernard, A. M.; Pierres, M.; Nielsen, P. F.; Ribel, U.; Watanabe, T.; Drucker, D. J.; Wagtmann, N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. *Proc. Natl. Acad. Sci. U. S. A.* **2000**, *97*, 6874–6879.
- (42) Gorrell, M. D.; Gysbers, V.; McCaughan, G. W. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. *Scand. J. Immunol.* **2001**, *54*, 249–264.
- (43) Beckenkamp, A.; Davies, S.; Willig, J. B.; Buffon, A. DPPIV/CD26: a tumor suppressor or a marker of malignancy? *Tumor Biol.* **2016**, *37*, 7059–7073.
- (44) Jansen, K.; Heirbaut, L.; Cheng, J. D.; Joossens, J.; Ryabtsova, O.; Cos, P.; Maes, L.; Lambeir, A. M.; De Meester, I.; Augustyns, K.; Van der Veken, P. Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold. *ACS Med. Chem. Lett.* **2013**, *4*, 491–496.
- (45) Jansen, K.; Heirbaut, L.; Verkerk, R.; Cheng, J. D.; Joossens, J.; Cos, P.; Maes, L.; Lambeir, A. M.; De Meester, I.; Augustyns, K.; Van der Veken, P. Extended structure activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP). *J. Med. Chem.* **2014**, *57*, 3053–3074.
- (46) Ryabtsova, O.; Jansen, K.; Van Goethem, S.; Joossens, J.; Cheng, J. D.; Lambeir, A. M.; De Meester, I.; Augustyns, K.; Van der Veken, P. Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 3412–3417.
- (47) Harmange, J. C.; Weiss, M. M.; Germain, J.; Polverino, A. J.; Borg, G.; Bready, J.; Chen, D.; Choquette, D.; Coxon, A.; DeMelfi, T.; DiPietro, L.; Doerr, N.; Estrada, J.; Flynn, J.; Graceffa, R. F.; Harriman, S. P.; Kaufman, S.; La, D. S.; Long, A.; Martin, M. W.; Neervannan, S.; Patel, V. F.; Potashman, M.; Regal, K.; Roveto, P. M.; Schrag, M. L.; Starnes, C.; Tasker, A.; Teffera, Y.; Wang, L.; White, R. D.; Whittington, D. A.; Zanon, R. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluations. *J. Med. Chem.* **2008**, *51*, 1649–1667.
- (48) Tykvar, J.; Sacha, P.; Barinka, C.; Knedlik, T.; Starkova, J.; Lubkowski, J.; Konvalinka, J. Efficient and versatile one-step affinity purification of in vivo biotinylated proteins: expression, characterization and structure analysis of recombinant human glutamate carboxypeptidase II. *Protein Expression Purif.* **2012**, *82*, 106–115.
- (49) Barinka, C.; Ptacek, J.; Richter, A.; Novakova, Z.; Morath, V.; Skerra, A. Selection and characterization of anticalins targeting human prostate-specific membrane antigen (PSMA). *Protein Eng., Des. Sel.* **2016**, *29*, 105–115.
- (50) Balaziova, E.; Busek, P.; Stremenova, J.; Sromova, L.; Krepla, E.; Lizcova, L.; Sedo, A. Coupled expression of dipeptidyl peptidase-IV and fibroblast activation protein-alpha in transformed astrocytic cells. *Mol. Cell. Biochem.* **2011**, *354*, 283–289.
- (51) Kelly, T.; Huang, Y.; Simms, A. E.; Mazur, A. Fibroblast activation protein-alpha: a key modulator of the microenvironment in multiple pathologies. *Int. Rev. Cell Mol. Biol.* **2012**, *297*, 83–116.
- (52) Gorrell, M. D. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. *Clin. Sci.* **2005**, *108*, 277–292.